“…Joint defects typically present elevated levels of tumor necrosis factor-α (TNF-α) and interleukins with inflamed synovium that downregulates extracellular matrix (ECM) production and the anabolic activity of the cells [57][58][59]. To reduce inflammation in joints, triamcinolone acetonide (TA) can be administered [60][61][62][63][64]; and site-specific delivery of drugs from biomaterials circumvents systemic pharmacokinetic challenges and off-target effects [65]. Scaffolds loaded with drugs/bioactives provide dual functionality in terms of local delivery of the payload in the extracellular environment, as well as serving as a support for the cells to organize in a 3D fashion [66][67][68].…”